Literature DB >> 21599865

Comprehensive risk assessments of diabetic patients from seven Asian countries: The Joint Asia Diabetes Evaluation (JADE) program.

Wing-Yee So1, Josephine Raboca, Leorino Sobrepena, Kun-Ho Yoon, Chaicharn Deerochanawong, Low-Tone Ho, Thep Himathongkam, Peter Tong, Greg Lyubomirsky, Gary Ko, Hairong Nan, Juliana Chan.   

Abstract

BACKGROUND: The aim of the web-based Joint Asia Diabetes Evaluation (JADE) program is to establish a registry for quality assurance, monitoring, and evaluation.
METHODS: The JADE electronic portal provides templates for data collection, supplemented by risk stratification, care protocols, and decision support. Herein, data from 3687 patients with Type 2 diabetes, enrolled over 15 months in 2007-2009 from seven Asian countries, are reported.
RESULTS: Of the patients, 46.1% were men, the median (range) age was 58 (15-93 years), and median disease duration was 6.5 (0-71) years; 16.2% had at least one cardiovascular-renal complication (10.0% coronary heart disease, 3.3% stroke, 3.1% peripheral vascular disease, 0.4% end-stage renal disease), 20.4% had diabetic retinopathy, 15.0% had sensory neuropathy, 7.5% had chronic kidney disease, and 20.7% of men had erectile dysfunction. Hypertension, dyslipidemia, and central obesity affected 84.6%, 76.8%, and 53.5% of patients, respectively. Treatment targets were HbA1c <7% in 35.3%, blood pressure <130/80 mmHg in 32.3%, and low-density lipoprotein-cholesterol <2.6 mmol/L in 34.0%. The rate of attaining one, two, and three targets was 38.7%, 23.4%, and 5.4%, respectively. Using the JADE Risk Engine, 60% of patients with clinical complications and 20% of those with multiple risk parameters were predicted to have a major event within 5 years. Older age, short disease duration, adherence to diet, control of other risk factors, and not smoking were independently associated with HbA1c <7% (all P < 0.05).
CONCLUSIONS: It is possible to use a web-based protocol to establish a registry for risk stratification and facilitate early intervention.
© 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21599865     DOI: 10.1111/j.1753-0407.2011.00115.x

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  19 in total

1.  The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.

Authors:  Fengmei Lian; Jiaxing Tian; Xinyan Chen; Zhibin Li; Chunli Piao; Junjie Guo; Licheng Ma; Lijuan Zhao; Chengdong Xia; Chong-Zhi Wang; Chun-Su Yuan; Xiaolin Tong
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

2.  Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.

Authors:  Li-Nong Ji; Ju-Ming Lu; Xiao-Hui Guo; Wen-Ying Yang; Jian-Ping Weng; Wei-Ping Jia; Da-Jin Zou; Zhi-Guang Zhou; De-Min Yu; Jie Liu; Zhong-Yan Shan; Yu-Zhi Yang; Ren-Ming Hu; Da-Long Zhu; Li-Yong Yang; Li Chen; Zhi-Gang Zhao; Qi-Fu Li; Hao-Ming Tian; Qiu-He Ji; Jing Liu; Jia-Pu Ge; Li-Xin Shi; Yan-Cheng Xu
Journal:  BMC Public Health       Date:  2013-06-21       Impact factor: 3.295

3.  Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study.

Authors:  Kenny Kung; Kai Ming Chow; Eric Ming-Tung Hui; Maria Leung; Shuk Yun Leung; Cheuk Chun Szeto; Augustine Lam; Philip Kam-Tao Li
Journal:  BMC Fam Pract       Date:  2014-01-10       Impact factor: 2.497

4.  Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study.

Authors:  Fang Fang Jiao; Colman Siu Cheung Fung; Carlos King Ho Wong; Yuk Fai Wan; Daisy Dai; Ruby Kwok; Cindy Lo Kuen Lam
Journal:  Cardiovasc Diabetol       Date:  2014-08-21       Impact factor: 9.951

5.  Is therapeutic inertia present in hyperglycaemia, hypertension and hypercholesterolaemia management among adults with type 2 diabetes in three health clinics in Malaysia? a retrospective cohort study.

Authors:  Boon-How Chew; Husni Hussain; Ziti Akthar Supian
Journal:  BMC Fam Pract       Date:  2021-06-11       Impact factor: 2.497

6.  Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.

Authors:  Itamar Raz; Matthew C Riddle; Julio Rosenstock; John B Buse; Silvio E Inzucchi; Philip D Home; Stefano Del Prato; Ele Ferrannini; Juliana C N Chan; Lawrence A Leiter; Derek Leroith; Ralph Defronzo; William T Cefalu
Journal:  Diabetes Care       Date:  2013-06       Impact factor: 19.112

7.  Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study.

Authors:  Fangfang Jiao; Colman Siu Cheung Fung; Yuk Fai Wan; Sarah Morag McGhee; Carlos King Ho Wong; Daisy Dai; Ruby Kwok; Cindy Lo Kuen Lam
Journal:  Cardiovasc Diabetol       Date:  2015-08-14       Impact factor: 9.951

8.  Measuring depression with CES-D in Chinese patients with type 2 diabetes: the validity and its comparison to PHQ-9.

Authors:  Yuying Zhang; Rose Z W Ting; Marco H B Lam; Siu-Ping Lam; Roseanne O Yeung; Hairong Nan; Risa Ozaki; Andrea O Y Luk; Alice P S Kong; Yun-Kwok Wing; Norman Sartorius; Juliana C N Chan
Journal:  BMC Psychiatry       Date:  2015-08-18       Impact factor: 3.630

Review 9.  Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States.

Authors:  Ronald C W Ma; Juliana C N Chan
Journal:  Ann N Y Acad Sci       Date:  2013-04       Impact factor: 5.691

10.  Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study.

Authors:  Lene Munch; Anne B Arreskov; Michael Sperling; Dorthe Overgaard; Filip K Knop; Tina Vilsbøll; Michael E Røder
Journal:  BMC Health Serv Res       Date:  2016-04-09       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.